Lument Finance Trust Receives NYSE Continued Listing Standard Notice

NYSE:LFT risks delisting after its share price averaged below $1.00 for 30 days.

What the company is saying

Lument Finance Trust, Inc. discloses it received a deficiency notice from the NYSE because its average closing share price was below $1.00 for 30 consecutive trading days. The company emphasizes that this is not a delisting notice and that its shares will continue trading during a six-month cure period ending January 24, 2027. Management states it is monitoring the share price and considering all alternatives to regain compliance, including a potential reverse stock split, but no specific action has been committed to. The language is neutral and procedural, focusing on regulatory requirements rather than operational or financial performance. The announcement highlights the compliance process and timeline but omits any discussion of underlying business fundamentals or recent financial results. No notable individuals or institutional figures are mentioned as being involved in the response.

What the data suggests

The only quantitative disclosure is that the average closing price of NYSE:LFT shares fell below $1.00 over a 30-day period, triggering non-compliance with NYSE Section 802.01C. The company now faces a six-month window, ending January 24, 2027, to restore its share price to at least $1.00 for both a single day and a 30-day average. No financial statements, earnings figures, or operational metrics are provided, so the underlying cause of the share price decline is not addressed. The announcement does not specify whether any remedial steps, such as a reverse split, are imminent or under board consideration. There is no evidence of recent financial improvement or deterioration beyond the share price metric. The lack of additional data prevents any assessment of financial trajectory, liquidity, or solvency. Investors are referred to the company's Form 10-K for risk factors, but no summary of those risks is included here.

Analysis

The announcement is a factual disclosure of a compliance deficiency notice from the NYSE due to the company's share price falling below $1.00 for 30 consecutive trading days. The language is procedural and regulatory, with no promotional or exaggerated tone. Most forward-looking statements are limited to the company's intent to monitor its share price and consider alternatives, such as a reverse stock split, but no specific remedial action has been committed to. There is no mention of large capital outlays, operational initiatives, or financial projections. The gap between narrative and evidence is minimal, as the company simply outlines the compliance process and possible next steps. No financial or operational progress is claimed, and no benefit realisation timeline is relevant beyond the six-month cure period.

Risk flags

• ●The company faces a clear risk of delisting from the NYSE if it fails to restore its share price to at least $1.00 within the six-month cure period. Delisting would reduce liquidity and could trigger forced selling by index funds or institutional holders.
• ●No concrete remedial actions, such as a reverse stock split or operational turnaround plan, have been announced. This lack of specificity increases uncertainty about management's ability or willingness to address the compliance issue.
• ●The announcement provides no financial or operational data beyond the share price deficiency, leaving investors without information on whether the underlying business is stable, improving, or deteriorating. This disclosure gap raises questions about the company's financial health and prospects.

Bottom line

This announcement signals a regulatory warning: NYSE:LFT's share price has fallen below the minimum required for continued NYSE listing, and the company now has a six-month window to resolve the issue. No operational or financial turnaround plan is disclosed, and management's stated options remain generic, with a reverse split only mentioned as a possibility. The absence of financial data leaves investors unable to assess whether the share price decline reflects deeper business problems. Unless and until the company announces a concrete remedial action or provides updated financials, the risk of delisting remains high. For now, this is a compliance update with no actionable turnaround plan, and the most important takeaway is that the company's NYSE listing is at risk unless decisive steps are taken.

Announcement summary

(NYSE:LFT) Lument Finance Trust, Inc. announced that it received notice from the New York Stock Exchange (the "NYSE") that the Company is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company's common stock was less than $1.00 over a consecutive 30 trading-day period. The notice is a notice of deficiency, not delisting, and does not currently impact the listing and trading of the Company's common stock on the NYSE. The Company may regain compliance at any time during the six-month cure period, which ends on January 24, 2027, if, on the last trading day of any calendar month during the cure period, the Company's common stock has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on such date. The Company's common stock will continue to be listed and trade on the NYSE during the cure period, subject to the Company's continued compliance with the NYSE's other continued listing standards. The Company intends to continue monitoring the market price of its common stock and is considering all available alternatives to regain compliance with the NYSE minimum share price requirement. Such alternatives may include a reverse stock split, subject to any required corporate approvals. LFT is a Maryland corporation focused on investing in, financing and managing a portfolio of commercial real estate debt investments.

Disagree with this article?